Wilfred Ngwa, Ph.D., Harvard Director of Global Health Catalyst at the Dana Farber/Harvard Cancer Center (DF/HCC), has recently commended Cannabis Science Inc (OTCMKTS:CBIS) for its presentation to the Harvard Medical School.

The Presentation

Cannabis Science has provided clear, long-term goals and compelling plans of action backed by extensive, factual research and knowledge.

Raymond Dabney, Cannabis Science CEO and President, has spearheaded the discussions together with Melvin Foote, Constituency for Africa, and Allen Herman, Ph.D., Cannabis Science Chief Medical Officer (CMO). They have presented a meaningful overview of the company and the Cannabis Science Research Foundation; elaborated the science behind cannabinoids and their therapeutic potentials; and facilitated deliberation of drug research and development (R&D) approaches among Harvard Medical School faculty members.

Stronger Partnership

According to Ngwa, the presentation of the company has been encouraging, further strengthening the strategic collaboration opportunities between Cannabis Science and the DF/HCC that are mutually beneficial.

“Partnerships between the Cannabis Science team and scientists here at the DF/HCC are expected to bring a deeper understanding of the potential effectiveness of cannabinoids in the treatment of cancer and other chronic diseases,” elaborated Ngwa.

Both Cannabis Science and the DF/HCC are thrilled to work closely together on new collaborative initiatives that seek to hasten drug R&D procedures for quick and successful commercialization approval by the US Food and Drug Administration (FDA).

Clinical Development Program for Respiratory Diseases

Earlier this month, Cannabis Science has also initiated a clinical development program that seeks to treat respiratory diseases using methods such as the intravenous (IV) administration of a cannabinol (CBD)/tetrahydrocannabinol (THC) therapy.

This is in line with one of the company’s goals of providing the best therapy delivery systems for patients. A treatment usually loses its potency depending on the delivery system or method employed. With IV administration, it is guaranteed that a therapy will not lose its potency in the process.

However, for some patients, it can get complicated when the treatment becomes trapped in their lungs. With the CBD/THC IV infusion of Cannabis Science, the substance trapped in the lungs can strengthen lung tissues.

On Friday, Cannabis Science has closed at $0.04.